Sandu Pharmaceuticals concluded its 41st Annual General Meeting on September 11, 2026, with shareholders approving key governance and financial resolutions for FY26. The meeting, held via video conferencing, saw the adoption of audited standalone financial statements and the declaration of a dividend on equity shares.

Key Governance Resolutions

Shareholders approved several ordinary and special business items critical to the company’s operational structure and compliance framework for the coming year.

Ordinary Business

• Adoption of Audited Standalone Financial Statements for the financial year ended March 31, 2026.
• Reappointment of Smt. Jayshree Sandu as a director retiring by rotation.
• Declaration of a dividend on equity shares for FY26.
• Appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a term of five years.

Special Business

• Ratification of Cost Auditor’s remuneration.
• Approval of material related-party transactions with Sandu Brothers Private Limited.
• Redesignation of Shri Balram Viswanathan as Chairman and Managing Director.
• Appointment of Smt. Dr Neeti Madan Kapre as a Non-Executive Independent Director.

Meeting Proceedings

The meeting commenced at 4:30 pm and concluded at 5:01 pm, adhering to guidelines issued by the Ministry of Corporate Affairs and SEBI. All six directors attended via video conference, including Chairman & Managing Director Balram Viswanathan and Independent Directors Ajit R Kantak, Vijay Kottapalli, and Dr Neeti Madan Kapre. Non-executive non-independent directors Jayshree Sandu and Shashank Sandu were also present.

Statutory Auditor M/s Dileep and Prithvi, represented by CA Himmat Mali, along with Secretarial Auditor CS Swapnil Dixit and Internal Auditors CA Akhil Pai and CA Uday Bapat, attended the proceedings. Cost Auditor M/s Shekhar Joshi & Co was also present.

Remote e-voting was facilitated from September 8 to September 10, 2026. Shareholders who did not vote remotely could cast their votes electronically during the meeting via NSDL. Scrutinizer Swapnil Dixit confirmed that consolidated voting results would be disseminated through stock exchanges and the company website within 48 hours of the meeting’s conclusion.

Sandu Pharmaceuticals has scheduled its 41st Annual General Meeting (AGM) for Friday, September 11, 2026. The meeting will be conducted via Video Conference or Other Audio-Visual Means in compliance with SEBI regulations and the Companies Act, 2013.

Meeting Details

The AGM is set to begin at 4:30 pm IST. Shareholders can access the Notice of AGM, explanatory statements, and the Annual Report for FY26 from the company’s website and the BSE Limited portal. The notice was published in Navhind Times and Navprabha on August 20, 2026.

E-Voting Process

Members holding shares as of the cut-off date of Friday, September 4, 2026, are eligible to vote. The company has enabled remote e-voting through National Securities Depository Limited (NSDL).

• Remote E-Voting Window: Commences at 10:00 am IST on Tuesday, September 8, 2026, and ends at 5:00 pm IST on Thursday, September 10, 2026.
• Voting During AGM: Members present via VC/OAVM who have not voted remotely may cast their votes during the meeting.
• Scrutinizer: Swapnil Dixit, ACS, of M/s. Swapnil J Dixit & Associates, has been appointed to scrutinize the voting process.

Record Date and Dividend

The Register of Members and Share Transfer Books will remain closed from September 4, 2026, to September 11, 2026, inclusive. Any dividend declared for FY26 will be paid to members recorded on the register as of the cut-off date.